Izotropic Publishes New FAQ Page for Investors, Analysts, and Healthcare Decision-Makers
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF)...
Day: September 16, 2025
Izotropic Publishes New FAQ Page for Investors, Analysts, and Healthcare Decision-Makers
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF)...
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management - GAITHERSBURG, Md.,...
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management - GAITHERSBURG, Md.,...
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted...
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted...
Marine Biologics Partners with Molecular Quantum Solutions to Accelerate Next-Generation Biomaterials Development
BERKELEY, Calif. and COPENHAGEN, Denmark, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today announced an exclusive strategic...
Marine Biologics Partners with Molecular Quantum Solutions to Accelerate Next-Generation Biomaterials Development
BERKELEY, Calif. and COPENHAGEN, Denmark, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biomaterials company Marine Biologics today announced an exclusive strategic...
CoreHealth Unveils CoreHealth NOW: A Turnkey Employee Wellness Solution for Today’s Workforce
Introducing CoreHealth NOW, your all-in-one wellness program designed to kick start your wellness initiatives with engaging challenges, health assessments, incentives,...
CoreHealth Unveils CoreHealth NOW: A Turnkey Employee Wellness Solution for Today’s Workforce
Introducing CoreHealth NOW, your all-in-one wellness program designed to kick start your wellness initiatives with engaging challenges, health assessments, incentives,...
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04...
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
In Australia and EuropeMADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),...
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
In Australia and EuropeMADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),...
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment...
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment...
Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
New U.S. patent provides IP coverage for the formulation to 2042Further expands Starton’s intellectual property portfolio surrounding its lead product...
Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
New U.S. patent provides IP coverage for the formulation to 2042Further expands Starton’s intellectual property portfolio surrounding its lead product...
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Medicines360, a women’s health innovation organization with a mission to be a...
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Medicines360, a women’s health innovation organization with a mission to be a...